What is MRD?
Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.
LEARN MORE ABOUT MRD
clonoSEQ for Patients
With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.
LEARN MORE ABOUT MRDclonoSEQ for Clinicians
clonoSEQ leverages the power of next-generation sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.
How clonoSEQ worksNews and Updates
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin’s Lymphoma.
December, 2020
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
View Press ReleaseAugust, 2020
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia.
View Press ReleaseWhat We’re Sharing
Follow Ushttps://t.co/acmAhTJHM1 MM pt & fndr of @myelomacrowd, @AhlstromJenny, discusses new #myeloma treatments & importance of #MRD. clonoSEQ is FDA-cleared to assess MRD in pts with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/sE39cuHWh3 pic.twitter.com/TqvukaILJn
— clonoSEQ (@clonoSEQ) May 13, 2021
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Contact Us
Make an inquiry to learn more about our products.